Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

out CYT003-QbG10

CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the ImmunodrugTM QbG10 which is comprised of the virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed to induce a potent Th1 type immune response in order to suppress an “allergic” Th2 type immune response. As initial clinical observations indicate, CYT003-QbG10 could thereby act by an allergen-independent mechanism of action so that it has potential as a causal and disease-modifying treatment for a broad range of different allergic diseases. CYT003-QbG10 is currently being studied in several clinical trials for the treatment of allergic rhinitis, asthma and atopic dermatitis.

About allergic diseases

Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. It is an exaggerated reaction by the patient’s immune system to a normally harmless substance such as various environmental proteins present in pollen, animal excrements, or food. According to the World Health Organization, more than 20% of the world population suffers from allergic diseases (WHO, 2002).

Seasonal allergic rhinitis due to grass pollen (commonly known as hay fever) is very common and affects 15-20% of the European population (WHO Europe, 2003). Three general approaches are commonly being pursued to relieve the symptoms of allergic diseases: avoidance of the allergen, prescription of medication that targets disease symptoms, and conventional immunotherapy, also known as desensitization. The latter is the only disease-modifying treatment available, however, it is applicable only for some defined allergies, is time-consuming (3-5 years) and inconvenient for the patients. T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/16/2014)... WESTPORT, Conn. , Sept. 16, 2014 /PRNewswire/ ... wholly owned subsidiary of TriStar Wellness Solutions(R), ... and marketer of advanced medical products, announced today ... platform has grown by 39 percent, and microdispersed ... year-to-date though August 2014.  Overall, TWSI expects third ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... 2014 The Lupus Foundation of America and ... today released results from UNVEIL: understanding the impact of ... lupus journey and the challenges not only for those ... UNVEIL study, which involved over 1,000 people with lupus ... on all aspects of life including family, work, finances, ...
Breaking Medicine Technology:HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 2HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 4New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5
(Date:9/16/2014)... use among teens in the United States is on the ... the new study also found that alcohol use, binge drinking ... the ages of 12 and 17 also dropped between 2002 ... 12 and older across the United States revealed that between ... age group also dropped from 8.9 percent to 5.2 percent. ...
(Date:9/16/2014)... equally preserved in cancer patients suffering from malignant spinal ... 10 Gy of radiation therapy (RT), compared to patients ... RT each, according to research presented today at the ... , Malignant spinal cord compression (MSCC) is a ... occurs when a tumor,s secondary deposit presses on the ...
(Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
(Date:9/16/2014)... -- While abnormalities in the adrenergic and noradrenergic ... thought to play a role in the development ... has been no genetic evidence of this connection. ... Columbia University,s Mailman School of Public Health and ... the ADRB2 gene and childhood adversity. For individuals ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3
... leading neuromodulation company, announced today that beginning January ... by Medicare for incomplete spinal cord injury patients ... Centers for Medicare and Medicaid Services (CMS) establishes ... stimulation (FES) devices including the NESS L300™ Foot ...
... changed in a heartbeat for successful freelance writer Lee Woodruff ... Tonight, was wounded while broadcasting from Iraq. Her experience as ... be the focus of her keynote address at URAC,s Best ... Exhibit, April 1-2, 2009 in Orlando, Fla. , ...
... 11 Rosalind Franklin University,of Medicine and Science ... the first in the nation to provide its students with ... The new,system enables medical educators to present students with individual ... has a proven,accuracy rate of over 90 percent. , ...
... Pain Therapeutics, Inc. (Nasdaq: PTIE ) has received a ... for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release ... determined that the NDA is not approved in its present form. ... believes additional non-clinical data will be required to support the approval ...
... 11 Preferred Management Corporation of,Shawnee, OK ... two hospitals near Amarillo, Texas. The hospitals, ... General Hospital in Wellington, are both,federally designated ... are administered by Preferred Management Corporation which ...
... to be ignoring message that methamphetamine is dangerous , , ... that utilizes graphic images actually may not be very ... Project (MMP), created in 2005, featured images that showed ... perceived success of the program had resulted in its ...
Cached Medicine News:Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 2Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 3Health News:Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 2Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 3Health News:Study Questions Value of Anti-Meth Campaign 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: